[Federal Register Volume 68, Number 231 (Tuesday, December 2, 2003)]
[Notices]
[Page 67473]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-29964]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to Section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(1)), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in Schedule II and prior to issuing a registration 
under Section 1002(a) authorizing the importation of such a substance, 
provide manufacturers holding registration for the bulk manufacture of 
the substance an opportunity for a hearing.
    Therefore, in accordance with Section 1301.34 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on May 30, 2003, 
Abbott Laboratories, 1776 North Centennial Drive, McPherson, Kansas 
67460-1247, made application by renewal to the Drug Enforcement 
Administration to be registered as an importer of Remifentanil (9739), 
a basic class of controlled substance listed in Schedule II.
    The firm plans to import the remifentanil to manufacture a 
controlled substance for distribution to its customers.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of this basic class of controlled substances may file 
written comments on or objections to the application described above 
and may, at the same time, file a written request for a hearing on such 
application in accordance with 21 CFR 1301.43 in such form as 
prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, DC 20537, Attention: Federal 
Register Representative, Office of Chief Counsel (CCD) and must be 
filed no later than (30 days from publication).
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice at 40 FR 43745-46 
(September 23, 1975), all applicants for registration to import basic 
class of any controlled substance in Schedule (or II are and will 
continue to be required to demonstrate to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration that the requirements for such registration pursuant to 
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1211.42(a), (b), (c), 
(d), (e), and (f) are satisfied.

    Dated: November 14, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-29964 Filed 12-1-03; 8:45 am]
BILLING CODE 4410-09-M